Rhythm Pharmaceuticals, Inc.
$87.72
▼
-2.08%
2026-04-21 09:16:00
rhythmtx.com
NGM: RYTM
Explore Rhythm Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.99 B
Current Price
$87.72
52W High / Low
$122.2 / $55.31
Stock P/E
—
Book Value
$2.07
Dividend Yield
—
ROCE
-51.31%
ROE
-90.45%
Face Value
—
EPS
$-3.11
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
414
Beta
2.14
Debt / Equity
41.54
Current Ratio
4.41
Quick Ratio
4.16
Forward P/E
-227.22
Price / Sales
30.37
Enterprise Value
$5.62 B
EV / EBITDA
-29.46
EV / Revenue
29.6
Rating
Strong Buy
Target Price
$137.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Whitehawk Therapeutics, Inc. | $4.23 | — | $193.98 M | — | -83.93% | -21.82% | $4.48 / $1.39 | $2.89 |
| 2. | NewcelX Ltd. | $2.83 | — | $12.13 M | — | 23.66% | 158.49% | $30.8 / $1.83 | $-11.28 |
| 3. | SeaStar Medical Holding Corporation | $4.63 | — | $16.77 M | — | -116.89% | -2.95% | $13.4 / $2.07 | $2.71 |
| 4. | Corbus Pharmaceuticals Holdings, Inc. | $10.62 | — | $188.36 M | — | -57.84% | -54.18% | $20.56 / $5.75 | $8.38 |
| 5. | NanoViricides, Inc. | $1.28 | — | $29.59 M | — | -127.59% | -77.53% | $2.23 / $0.85 | $0.51 |
| 6. | ProMIS Neurosciences, Inc. | $11.45 | — | $24.63 M | — | 3267.2% | -5.22% | $39.75 / $6.27 | $-0.58 |
| 7. | Cogent Biosciences, Inc. | $37 | — | $6.05 B | — | -38.16% | -73.7% | $43.73 / $4.12 | $3.4 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 57.25 M | 51.3 M | 48.5 M | 32.7 M | 41.83 M | — |
| Operating Profit | -47.06 M | -52.65 M | -45.3 M | -47 M | -41.26 M | — |
| Net Profit | -47.51 M | -52.9 M | -46.63 M | -49.5 M | -43.29 M | — |
| EPS in Rs | -0.7 | -0.77 | -0.68 | -0.72 | -0.63 | -0.73 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 189.76 M | 130.13 M | 77.43 M | 23.64 M |
| Operating Profit | -192.02 M | -265.5 M | -184.36 M | -179.16 M |
| Net Profit | -196.54 M | -260.6 M | -184.68 M | -181.12 M |
| EPS in Rs | -2.88 | -3.82 | -2.7 | -2.65 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 480.2 M | 392.27 M | 332.75 M | 382.48 M |
| Total Liabilities | 210.17 M | 227.72 M | 162.99 M | 118.22 M |
| Equity | 270.03 M | 164.55 M | 169.76 M | 264.26 M |
| Current Assets | 466.92 M | 374.2 M | 308.27 M | 354.24 M |
| Current Liabilities | 105.94 M | 115.52 M | 55.2 M | 39.81 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -115.67 M | -113.88 M | -136.16 M | -173.43 M |
| Investing CF | -137.15 M | -48.17 M | -5.67 M | 28.03 M |
| Financing CF | 217.96 M | 191.24 M | 74.37 M | 213.83 M |
| Free CF | -116.63 M | -113.88 M | -136.2 M | -177.71 M |
| Capex | -0.95 M | — | -0.05 M | -4.28 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 45.83% | 68.06% | 227.56% | — |
| Earnings Growth % | 24.58% | -41.11% | -1.97% | — |
| Profit Margin % | -103.57% | -200.27% | -238.52% | -766.22% |
| Operating Margin % | -101.19% | -204.04% | -238.1% | -757.92% |
| Gross Margin % | 89.73% | 89.73% | 87.99% | 90.98% |
| EBITDA Margin % | -91.76% | -182.97% | -217.58% | -737.14% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.